Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

Merck & Co. says its third-quarter profit plunged 35 per cent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges.
The world’s second-biggest drugmaker says net income was $1.12 billion, or 38 cents per share, down from $1.73 billion, or 56 cents per share, a year earlier.
The maker of Type 2 diabetes pill Januvia says that excluding the one-time items, net income would have been $2.73 billion, or 92 cents per share. Analysts surveyed by FactSet were expecting 88 cents per share.
Revenue totalled $11.03 billion, down 4 per cent. That missed expectations for $11.13 billion in revenue.
The company lowered its 2013 profit forecast to $1.61 to $1.79 per share, from its July forecast of $1.84 to $2.05.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.